FMP
Akouos, Inc.
AKUS
NASDAQ
Inactive Equity
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
13.29 USD
0 (0%)
AKUS Financial Statements
Year
2021
2020
2019
2018
Current Assets
236.16M
310.64M
26.14M
23.34M
Cash & Short Term Investments
232.45M
308.01M
25.08M
23.02M
Cash And Cash Equivalents
121.91M
68.93M
25.08M
23.02M
Short Term Investments
110.55M
239.08M
0
0
Net Receivables
0
0
0
0
Inventory
0
0
0
0
Other Current Assets
3.71M
2.63M
1.06M
319k
Non-Current Assets
42.59M
22.71M
19.02M
2.44M
Property, Plant & Equipment
40.14M
21.35M
0
0
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
0
Tax Assets
0
0
0
0
Other Non-Current Assets
2.45M
1.36M
19.02M
2.44M
Other Assets
0
0
0
0
Total Assets
278.75M
333.35M
45.16M
25.78M
-
-
-
-
Current Liabilities
16.8M
10.71M
5.94M
4.93M
Accounts Payable
1.28M
895k
339k
427k
Short Term Debt
671k
1.11M
641k
0
Tax Payables
0
0
0
0
Deferred Revenue
0
0
0
0
Other Current Liabilities
14.85M
8.7M
4.96M
4.51M
Total Current Liabilities
16.8M
10.71M
5.94M
4.93M
Total Non-Current Liabilities
28.3M
12.03M
72.02M
28.07M
Long-Term Debt
28.3M
12.03M
0
0
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
0
0
72.02M
28.07M
Total Liabilities
45.1M
22.74M
77.96M
33.01M
Other Liabilities
0
0
0
0
Stockholders Equity
233.65M
310.61M
-32.8M
-7.23M
Common Stock
3k
3k
0
0
Retained Earnings
-168.4M
-81.72M
-33.12M
-7.38M
Accumulated Other Comprehensive Income/Loss
-202k
13k
-394k
-60k
Other Shareholders Equity
402.24M
58.97M
717k
214k
Total Liabilities and Stockholders Equity
278.75M
333.35M
45.16M
25.78M
All figures are in USD.
